Drug Trial Radar · NCT04121143
A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in Adults
Last checked: Nov 19, 2026Latest source record: Mar 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
120
Planned (sponsor's estimate)
Start
Nov 9, 2019
Primary completion
Jun 30, 2020
Study completion Dec 30, 2020
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 9, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, placebo-controlled, parallel-randomized, double-blind, phase II study to investigate the efficacy, safety, tolerability and Pharmacokinetics of SHR-1314 injection with moderate to severe plaque psoriasis in adults
Conditions
- Plaque Psoriasis
Interventions
IL-17A AntagonistBiological
SHR-1314 subcutaneous injection
PlacebosBiological
placebo subcutaneous injection to maintain consistency and to prevent blindness
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of subjects reach to PASI 75 response at 16 weeksTime frame: 16 week
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Hengrui Pharmaceutical Co., Ltd.
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.